Market Access Beyond GLP-1Rs: emerging targets poised to gain share of obesity market Pharmaceutical TechnologyNon-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.Market AccessMetabolic & GLP-1Read full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Technology Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031. Market AccessMetabolic & GLP-1Read full story Post navigation Previous: FDA Policy Tracker 2026: Psychedelics get a boostNext: S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer Related Stories Market Access Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing pharminent September 2, 2026 Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026